- Home
- IMMX vs PBHC Comparison
IMMX vs PBHC Comparison
Compare IMMX & PBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- PBHC
- Stock Information
- Founded
- IMMX 2014
- PBHC 1859
- Country
- IMMX United States
- PBHC United States
- Employees
- IMMX N/A
- PBHC N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- PBHC Major Banks
- Sector
- IMMX Health Care
- PBHC Finance
- Exchange
- IMMX Nasdaq
- PBHC Nasdaq
- Market Cap
- IMMX 82.6M
- PBHC 92.9M
- IPO Year
- IMMX 2021
- PBHC N/A
- Fundamental
- Price
- IMMX $3.05
- PBHC $15.05
- Analyst Decision
- IMMX Strong Buy
- PBHC
- Analyst Count
- IMMX 1
- PBHC 0
- Target Price
- IMMX $8.00
- PBHC N/A
- AVG Volume (30 Days)
- IMMX 453.7K
- PBHC 6.6K
- Earning Date
- IMMX 11-11-2025
- PBHC 11-03-2025
- Dividend Yield
- IMMX N/A
- PBHC 2.66%
- EPS Growth
- IMMX N/A
- PBHC N/A
- EPS
- IMMX N/A
- PBHC 0.28
- Revenue
- IMMX N/A
- PBHC $39,015,000.00
- Revenue This Year
- IMMX N/A
- PBHC N/A
- Revenue Next Year
- IMMX N/A
- PBHC N/A
- P/E Ratio
- IMMX N/A
- PBHC $53.66
- Revenue Growth
- IMMX N/A
- PBHC N/A
- 52 Week Low
- IMMX $1.34
- PBHC $13.55
- 52 Week High
- IMMX $3.20
- PBHC $19.86
- Technical
- Relative Strength Index (RSI)
- IMMX 77.89
- PBHC 46.21
- Support Level
- IMMX $2.31
- PBHC $15.08
- Resistance Level
- IMMX $2.82
- PBHC $15.31
- Average True Range (ATR)
- IMMX 0.25
- PBHC 0.06
- MACD
- IMMX 0.08
- PBHC -0.04
- Stochastic Oscillator
- IMMX 95.41
- PBHC 0.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.